Landiolol
![]() | |
| Systematic (IUPAC) name | |
|---|---|
|
[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl 3-[4-[(2S)-2-hydroxy-3-[2-(morpholine-4-carbonylamino)ethylamino]propoxy]phenyl]propanoate | |
| Clinical data | |
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | IV |
| Legal status |
|
| Identifiers | |
| CAS Number |
133242-30-5 |
| ATC code | none |
| PubChem | CID 114905 |
| ChemSpider |
102855 |
| UNII |
62NWQ924LH |
| Chemical data | |
| Formula | C25H39N3O8 |
| Molar mass | 509.59 g/mol |
| |
| |
| | |
Landiolol (INN) is a drug which acts as a highly cardioselective, ultra short-acting beta blocker. It is used as an anti-arrhythmic agent.
References
- Yoshiya I (December 1998). "[Landiolol hydrochloride, a new sympathetic beta blocker]". Masui (in Japanese). 47 Suppl: S126–32. PMID 9921175.
- Ogata J, Okamoto T, Minami K (2003). "Landiolol for the treatment of tachyarrhythmia associated with atrial fibrillation". Can J Anaesth 50 (7): 753. doi:10.1007/BF03018726. PMID 12944459.
This article is issued from Wikipedia - version of the Saturday, April 02, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.
